First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro.

First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro.

Item

http://www.wikidata.org/entity/Q34269238

Q34269238

about

Mechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone Remodeling Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: a prospective multicenter study The effects of proteasome inhibitors on bone remodeling in multiple myeloma.Pit- and trench-forming osteoclasts: a distinction that matters Mitotic catastrophe and cell cycle arrest are alternative cell death pathways executed by bortezomib in rituximab resistant B-cell lymphoma cells Proteasome inhibitors and bone disease.Can we change the disease biology of multiple myeloma?The effects of bortezomib on bone disease in patients with multiple myeloma.The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling.N-terminal pro-C-type natriuretic peptide in serum associated with bone destruction in patients with multiple myeloma.Bone healing in multiple myeloma: a prospective evaluation of the impact of first-line anti-myeloma treatment.Bortezomib for the treatment of multiple myeloma.The Proteasome and Myeloma-Associated Bone Disease.Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study.Clinical significance of osteoblast precursors and osteoclast precursors in earlier diagnosis and monitoring of myeloma bone disease.High-dose therapy improves the bone remodelling compartment canopy coverage and bone formation in multiple myeloma.Myeloma bone disease: Pathophysiology and management.An engineered, quantifiable in vitro model for analysing the effect of proteostasis-targeting drugs on tissue physical properties Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma

P2860

Q28082335-1EBBAB7E-FEED-492D-9C97-D5358A79B2E5 Q33891364-6307EBAF-EB57-4AE7-B5BB-7643B32DC1FE Q33918020-5260860A-6637-4555-BB46-C68923CC579D Q36333959-6185A649-DBEF-4D59-8419-DDB7F1960AC0 Q37706483-D45C573D-D428-4F37-8390-2A7CA18D8F31 Q38021042-DDF7E0D7-D72E-47EB-86B7-A6C3BAB53CB7 Q38062038-94A09832-33A3-4BB3-9EE7-2FDCE4B69CE0 Q38163937-80C07B4B-26C8-41EB-A999-B5F91CACB647 Q39212192-6F4F0609-366F-4AC3-85FB-91892EB63C57 Q41586677-E7EDF50D-4E8E-4E20-8660-49E8AA7825C4 Q42388534-61A628AD-FC3B-4635-AD27-1AE45F0F7C73 Q47604607-A0A38514-4416-43A1-95B0-4A2F5B4FBC5F Q47696279-E6ED6ED6-EA68-4B8E-B4DF-60D2857D734B Q48314232-44D6D904-F0C2-433A-849A-AF82E1C87155 Q52872947-43C625B5-933C-4007-8CB3-9165268220F9 Q53407176-34E6FEBB-9380-4440-9655-A59C7F180756 Q55209965-BF7A0713-87B4-43C0-8534-18E173FDE140 Q57128114-504967C1-CC1C-4F64-B255-9499B1422681 Q57904558-1482E7DD-1A1E-4081-9CE4-3F71E00A36FE

P2860

First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro.

Item

http://www.wikidata.org/entity/Q34269238

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu